MedTrace Logo

Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer

NCT05551767 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-09-23

No results posted yet for this study

Summary

patients with locally advanced cancer of oropharynx, hypopharynx or larynx and CPS\>1 will recieve 3 cycles of induction immunochemotherapy with platinum, 5-FU and pembrolizumab followed by (chemo)radiation.

Conditions

  • Neck Cancer

Interventions

DRUG

Pembrolizumab

3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\\m2, 5-FU 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg)

Sponsors & Collaborators

  • Moscow City Oncology Hospital No. 62

    collaborator OTHER_GOV

  • Moscow Clinical Scientific Center

    collaborator OTHER

  • City Clinical Oncology Hospital No 1

    lead OTHER_GOV

Principal Investigators

  • Vsevolod N Galkin, Professor · City Clinical Oncology Hospital No 1

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-30
Primary Completion
2023-12-30
Completion
2024-12-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05551767 on ClinicalTrials.gov